Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 19, 2019

Study Completion Date

June 19, 2019

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

aMIL

On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.

DRUG

No aMIL

On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01858558 - Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma | Biotech Hunter | Biotech Hunter